Navigation Links
SpectraScience Awarded European Patent for Its Optical Biopsy System for Tissue Diagnosis
Date:12/1/2008

SAN DIEGO, Dec. 1 /PRNewswire-FirstCall/ -- SpectraScience, Inc. (OTC Bulletin Board: SCIE), a San Diego based medical device company, today announced that it has been awarded a European patent for its Optical Biopsy System for Tissue Diagnosis.

Jim Hitchin, SpectraScience's CEO, commented, "This patent is important to the Company's optical biopsy technology because it provides protection in the areas of tissue surveillance, characterization, diagnosis and treatment. It supports the Company's fundamental technology of non-invasive, low-level laser diagnosis of pre-cancerous and cancerous tissue. This is another key patent in our expanding intellectual property portfolio that underscores our commitment at SpectraScience to develop better, more reliable cancer screening technologies."

Hitchin added, "Accurate imaging is critical to earlier and more effective identification of normal, pre-cancerous and/or cancerous tissue, and this invention provides methods of making our screening devices more useful to the physician and, more importantly, to the patient."

SpectraScience holds approximately 60 patents worldwide that have been issued or are pending on its WavSTAT(R) Optical Biopsy and LUMA(R) Cervical Imaging Systems. These devices are used to diagnose tissue quickly to determine if it is normal, pre-cancerous, or cancerous. The WavSTAT and LUMA Systems are currently approved by the FDA for detecting pre-cancerous and cancerous tissue in the colon and cervix, respectively. An evaluation of the WavSTAT for detection of pre-cancers in the throat ("Barrett's esophagus") is being tested.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.

About SpectraScience, Inc.

SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. The WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative technology for clinical use. The Company's LUMA imaging technology has received FDA approval for an optical non-invasive system that is proven to more effectively detect cervical cancer precursors than conventional methods available in the market today.

     Contact:

     SpectraScience, Inc.
     Jim Hitchin, Chief Executive Officer
     (858) 847-0200 x201

     Hayden Communications
     Investor Relations
     Todd Pitcher
     (858)-518-1387

'/>"/>
SOURCE SpectraScience, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. SpectraScience Receives Final European Certification
2. SpectraScience Acquires Luma Imaging Corporation
3. SpectraScience, Inc. Retains Hayden Communications
4. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
5. SpectraScience Secures Distribution for WavSTAT(R) Cancer Diagnosis System in Italy
6. SpectraScience Adds Industry Veteran to Executive Team
7. SpectraScience Awarded Patent for Correcting Image Misalignment
8. SpectraScience Delivers Cancer Diagnosis System to Mayo Clinic and UCSD/VA for Detecting Esophageal Dysplasia in Patients
9. SpectraScience Announces Updates
10. UVa researcher awarded $3.6 million grant to fight drug-resistant bacteria
11. Southwest Ambulance Awarded Exclusive, 3-Year Contract Extension in Peoria, Arizona
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... ... May 26, 2016 , ... ... for the Foundation Fighting Blindness, Long Island Chapter on June 4, 2016, 1:30-3:30 ... , Dr. Maisel, founder of Retina Group of New York , is ...
(Date:5/26/2016)... ... , ... Memorial Day Weekend marks the unofficial start of summer and the ... make sure your family and vehicle are ready to hit the road this weekend. ... deaths and an additional 50,500 serious injuries from motor vehicle crashes during the three-day ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The ... to host a six-week smoking cessation class starting June 6 at their clinic in ... http://www.gnahec.org . , Additionally, the Lung Institute has created a free downloadable 4 ...
(Date:5/26/2016)... ... May 26, 2016 , ... American orthopedic ... medical officer of Blue Horizon International (BHI), Brian Mehling, M.D., spoke at an ... during May 5-6, 2016 in Chicago, IL, USA. Dr. Mehling’s presentation was focused ...
(Date:5/26/2016)... ... May 26, 2016 , ... Power Systems, a ... first PowerWave Instructor Certification Course in Stoughton, Massachusetts. The course was led by ... through the 8 hour interactive course to qualify participants as certified PowerWave trainers. ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... According to market research "Global ... Demand Forecast to 2022 - Industry Insights by Type ... by P&S Market Research, the global insulin delivery device ... it is expected to grow at a CAGR of ... segment is expected to witness the fastest growth at ...
(Date:5/25/2016)... , May 25, 2016 Digital Health ... to it by the US Patent and Trademark ... technology includes proprietary processes for electronic opt-­in and ... and wellness programs, HIPAA compliance and otherwise. ... "Our technology allows for ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology: